Viromed Medical AG (Q11) — Strategic Asset Allocation Index
Viromed Medical AG (Q11) has a Strategic Asset Allocation Index of 4.9% as of September 2025. Strategic assets (PP&E of €- plus long-term investments of €13.15 Million) total €13.15 Million, measured against net assets of €269.20 Million. A higher index reflects capital-intensive or investment-heavy strategies where strategic assets dominate the equity base. See debt-free asset ratio of Viromed Medical AG to measure how much of total assets are equity-financed.
SAAI
Strategic Assets
PP&E
Net Assets
Viromed Medical AG Strategic Asset Allocation Index (2022–2024)
This chart shows how Viromed Medical AG's Strategic Asset Allocation Index has evolved across 3 annual periods from 2022 to 2024. As of September 2025, the index stands at 4.9%, representing strategic assets of €13.15 Million against net assets of €269.20 Million EUR. For live market cap and overall valuation, see Q11 company net worth.
Annual Strategic Asset Allocation Index for Viromed Medical AG (2022–2024)
The table below presents the year-by-year Strategic Asset Allocation Index for Viromed Medical AG from 2022 to 2024, covering 3 annual filings. Each row shows PP&E, long-term investments, strategic assets combined, net assets, the index percentage, and the change in percentage points compared to the prior year. See Q11 total equity for net asset value and shareholders' equity analysis.
| Year | SAAI | Strategic Assets (EUR) | PP&E | LT Investments | Net Assets | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 10.7% | €21.60 Million | €- | €21.60 Million | €201.16 Million | ▼ -31.3 pp |
| 2023 | 42.0% | €27.01 Million | €- | €27.01 Million | €64.28 Million | ▲ +42.0 pp |
| 2022 | 0.0% | €0.00 | €- | €0.00 | €63.23 Million | — |